QIAGEN

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell QIAGEN and other ETFs, options, and stocks.

About QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. 

CEO
Thierry L. Bernard
CEOThierry L. Bernard
Employees
5,765
Employees5,765
Headquarters
Venlo, Limburg
HeadquartersVenlo, Limburg
Founded
1996
Founded1996
Employees
5,765
Employees5,765

QGEN Key Statistics

Market cap
10.54B
Market cap10.54B
Price-Earnings ratio
24.94
Price-Earnings ratio24.94
Dividend yield
0.52%
Dividend yield0.52%
Average volume
2.86M
Average volume2.86M
High today
$51.79
High today$51.79
Low today
$50.81
Low today$50.81
Open price
$51.24
Open price$51.24
Volume
2.55M
Volume2.55M
52 Week high
$57.82
52 Week high$57.82
52 Week low
$37.63
52 Week low$37.63

Stock Snapshot

The current QIAGEN(QGEN) stock price is $50.95, with a market capitalization of 10.54B. The stock trades at a price-to-earnings (P/E) ratio of 24.94 and offers a dividend yield of 51.7%.

As of 2026-02-08, QIAGEN(QGEN) stock has fluctuated between $50.81 and $51.79. The current price stands at $50.95, placing the stock +0.3% above today's low and -1.6% off the high.

The QIAGEN(QGEN)'s current trading volume is 2.55M, compared to an average daily volume of 2.86M.

In the last year, QIAGEN(QGEN) shares hit a 52-week high of $57.82 and a 52-week low of $37.63.

In the last year, QIAGEN(QGEN) shares hit a 52-week high of $57.82 and a 52-week low of $37.63.

QGEN News

TipRanks 22h
QIAGEN Earnings Call: Growth Pillars Offset Near-Term Drag

Qiagen ((QGEN)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powe...

TipRanks 2d
Qiagen price target raised to $53 from $48.42 at Baird

Baird analyst Cathy Ramsey Schulte raised the firm’s price target on Qiagen (QGEN) to $53 from $48.42 and keeps a Neutral rating on the shares. The firm updated...

TipRanks 2d
Qiagen Tops 2025 Guidance and Sets Ambitious 2026 Growth Targets

Qiagen ( (QGEN) ) just unveiled an announcement. On February 4, 2026, Qiagen reported unaudited results for the fourth quarter and full year ended December 31,...

Analyst ratings

67%

of 24 ratings
Buy
29.2%
Hold
66.7%
Sell
4.2%

More QGEN News

Simply Wall St 3d
Qiagen Automation Push And New Board Voice Shape Growth Outlook

Qiagen (NYSE:QGEN) introduced new laboratory automation platforms at SLAS 2026, including the public debut of its QIAsprint Connect system. The company highlig...

Qiagen Automation Push And New Board Voice Shape Growth Outlook
TipRanks 5d
BlackRock Discloses Significant Stake in QIAGEN

Qiagen ( (QGEN) ) has shared an announcement. QIAGEN has disclosed that the Dutch financial markets regulator AFM notified the company of a substantial holding...

TipRanks 6d
Qiagen price target lowered to EUR 43 from EUR 44.21 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Qiagen (QGEN) to EUR 43 from EUR 44.21 and keeps an Equal Weight rating on the shares. Published first on The...

People also own

Based on the portfolios of people who own QGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.